The first successful prostate cancer biomarker study was the previously mentioned PROfound study, which demonstrated that patients with BRCA1, BRCA2, and ATM alterations responded better to PARP inhibitors and achieved a longer radiographic PFS and OS. This evidence concerns the gene PARP1 and prostate cancer.